Prostate cancer (\[Mendelian Inheritance in Man 176807\]) is the most commonly diagnosed nonskin malignancy and the second leading cause of cancer-related death among men in United States and first leading cause of death among Hispanics/Latinos[@b1][@b2]; and in Asian countries, especially in China, the incidence of prostate cancer is increasing[@b3]. Worldwide, the disease is the second most common cancer in men after lung cancer[@b4]. Prostate cancer is a complicated and multifactorial disease. The precise etiology and pathological mechanism of prostate cancer remains unclear. Age, family history, and ethnicity are the most consistently addressed risk factors associated with prostate cancer. However, age and inherited factors are estimated to be responsible for 5% to 9% percentage of prostate cancer[@b5]. Therefore, identifying a preventable cause of prostate cancer would produce an important influence of public health.

The substantial differences aforementioned in incidence of prostate cancer worldwide may be due to ethnic variation[@b6]. Therefore, certain researchers indicated that different levels of androgens across varying ethnicity may contribute to these differences[@b6][@b7]. The exact mechanism through which androgen is involved in the etiology of prostate cancer remains unclear. The androgen receptor gene \[Mendelian Inheritance in Man 313700\] is located at Xq11.2-q12, and the length of androgen receptor gene is more than 90 kb[@b8]. The androgen receptor gene is comprised of eight exons that encode four functional domains, which include the transactivation domain, the DNA binding domain, a hinge region, and the carboxyl-terminal ligand binding domain[@b9]. There are two main polymorphisms including CAG and GGN repeats in the androgen receptor gene. Moreover, CAG was associated with the transcriptional activity of the AR in response to ligand binding. Therefore, the correlation between these polymorphisms of androgen receptor and risk of prostate cancer has received much attention. Three published meta-analyses[@b6][@b10][@b11] and several narrative reviews[@b12][@b13][@b14][@b15] have addressed the association between the repeat polymorphisms and prostate cancer susceptibility. However, the conclusions of these previous meta-analyses were not consistent and the narrative reviews could not quantify the estimate. Additionally, more studies have been published since the most recent meta-analysis. Therefore, we performed the present meta-analysis aimed to provide a more precise and comprehensive result for the relationship between CAG and GGN repeat polymorphisms of androgen receptor gene and prostate cancer susceptibility.

Methods
=======

Eligible criteria
-----------------

For inclusion in this meta-analysis, the publication had to meet the following eligible criteria: (1) the exposure was androgen receptor gene CAG and GGN repeat polymorphisms; (2) populations were men with prostate cancer (cases) without prostate cancer (controls); (3) the outcome was incident of prostate cancer; (4) the study design was retrospective or prospective (i.e. nested) case-control study; (5) study provided distribution of genotype, odds ratio (OR) and corresponding 95% confidence interval (CI), mean difference (MD) and corresponding standard error (SE), and mean repeats in case and control groups with related SE. For duplicated publication, we included the most recent or that providing the most information. If one publication provided different groups of ethnicity, we considered the each group as a separate study. We conducted the meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement in reporting meta-analysis. The protocol (registration number: CRD42016036971) of the meta-analysis was published in the PROSPERO register (<http://www.crd.york.ac.uk/PROSPERO/>).

Search strategy
---------------

A comprehensively literature search was performed in PubMed, Embase, CBM, CNKI and Wanfang databases up to March, 2016, without restriction to regions, publication types, or languages. The search strategy was as following: ("polymorphism" AND "prostate cancer" AND "androgen receptor"). In addition, references in the recent reviews or meta-analysis and included articles were identified for any further potential related studies.

Data extraction
---------------

Data from the included studies were extracted and summarized independently by two authors (HW and XT-Z). Any disagreement was resolved by discussion of which data should be extracted. The following information was extracted: last name of first author, publication year, country of study, ethnicity, study design, control status, sample size, age of the cases and controls, percentage of advanced prostate cancer cases (T3-T4, M0; T0-T4, M1), the repeat cutpoint of polymorphisms, mean number of repeats in case and control groups with related SE, dichotomous data (short versus long repeats), and estimate with corresponding 95% CI (including OR for dichotomous data and continuous data). We defined the long CAG and GGN repeats as ≥22 and \>16 repeats as previously published[@b6], respectively. Otherwise, \<22 and ≤16 were short CAG and GGC repeats, respectively.

Statistical analysis
--------------------

We calculated ORs and 95% CIs for short CAG repeats (\<22) versus long CAG repeats (≥22) and short GGN repeats (≤16) versus long GGN repeats (\>16) using dichotomous data[@b6]. We summarized ORs and corresponding 95% CIs for per decrement of CAG and GGN repeats. We also summarized the MDs in number of repeats between cases and controls. In this meta-analysis, all pooled analyses were performed with random-effects model using the method of DerSimonian-Laird, with the estimate of heterogeneity being taken from the from the Mantel-Haenszel model. Subgroup analyses were also performed according to ethnicity (Caucasian, Asian, Africa, or Hispanic), study design (prospective, i.e. nested or retrospective case-control study), control status, and histology grade of prostate cancer (localized and advanced). In addition, meta-regression analysis was also performed for interaction of between-group. Sensitivity analysis was performed by removing each study at a time. Publication bias was detected using contour-enhanced funnel plot and Egger's linear regression method. Statistical analysis was performed using Stata 12.0 software. A two-sided P value of 0.05 was used, except for heterogeneity test (0.1).

Results
=======

Study characteristics
---------------------

A total of 717 relevant publications were identified from the electronic literature search. The PRISMA flow diagram was presented in [Fig. 1](#f1){ref-type="fig"}, which shows the detail of inclusion and exclusion of studies. Ultimately, 51 publications[@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66] were included in the meta-analysis, in which 51 publications[@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66] with 61 case-control studies (14 803 cases and 18 888 controls, [Fig. 2](#f2){ref-type="fig"}) for CAG repeats and 14 publications[@b16][@b18][@b20][@b21][@b23][@b24][@b32][@b33][@b35][@b47][@b53][@b54][@b56][@b57] with 16 case-control studies (2986 cases and 3705 controls, [Fig. 3](#f3){ref-type="fig"}) for GGN repeats. The characteristics of included studies were shown in [Table 1](#t1){ref-type="table"}.

Association between CAG repeats polymorphism and prostate cancer risk
---------------------------------------------------------------------

Fifty-one case-control studies conveyed data on the short versus long CAG repeats. The pooled analysis showed that men with short CAG repeats carried higher risk of prostate cancer than long CAG repeats (OR = 1.31, 95% CI 1.16 to 1.47; I^2^ = 74.9%, P for heterogeneity \<0.01; [Fig. 4](#f4){ref-type="fig"}). Thirty-three case-control studies presented the data for per one CAG decrement and the summarized OR was 1.04 (95% CI 1.02 to 1.07; I^2^ = 83.4%, P for heterogeneity \<0.01; [Fig. 5](#f5){ref-type="fig"}) for men with per one CAG decrement. The aggregated analysis suggested that prostate cancer cases seemed to have on average 0.85 fewer CAG repeat length than controls (MD = −0.85, 95% CI −1.28 to −0.42; I^2^ = 88.7%, P for heterogeneity \<0.01; [Fig. 6](#f6){ref-type="fig"}) with 23 case-control studies.

Association between GGN repeats polymorphism and prostate cancer risk
---------------------------------------------------------------------

Sixteen case-control studies provided data on the short versus long GGN repeats. The pooled results showed that men with short GGN repeats carried higher risk of prostate cancer than long GGN repeats (OR = 1.38, 95% CI 1.05 to 1.82; I^2^ = 69.1%, P for heterogeneity \<0.01; [Fig. 7](#f7){ref-type="fig"}). Six case-control studies presented the data for per one GGN decrement and the summarized OR was 0.99 (95% CI 0.95 to 1.03; I^2^ = 0.0%, P for heterogeneity = 0.93; [Fig. 8](#f8){ref-type="fig"}) per GGN. The summarized MD of GGN repeats showed no significant difference between the prostate cancer cases and controls (MD = 0.05, 95% CI −0.09 to 0.18; I^2^ = 0.0%, P for heterogeneity = 0.95; [Fig. 9](#f9){ref-type="fig"}) with six case-control studies.

Haplotype analysis of CAG and GGN repeat polymorphisms
------------------------------------------------------

Six case-control studies provided data for haplotype analysis. The estimated ORs were 2.06 (95% CI 1.29 to 3.29; I^2^ = 69.3%, P for heterogeneity = 0.006), 1.79 (95% CI 1.08 to 2.96; I^2^ = 75.8%, P for heterogeneity = 0.001), and 1.21 (95% CI 0.94 to 1.56; I^2^ = 0, P for heterogeneity = 0.99) for haplotypes CAG \<22/GGN ≤16, CAG \<22/GGN \>16, and CAG ≥22/GGN ≤16 compared with CAG ≥22/GGN \>16 ([Fig. 10](#f10){ref-type="fig"}).

Subgroup, meta-regression and sensitivity analysis
--------------------------------------------------

Subgroup analyses were conducted according to ethnicity, study design, control status, and histology grade of prostate cancer. The results of subgroup analyses showed that the elevated risk of prostate cancer in both CAG and GGN repeat polymorphisms were more predominant among Caucasian populations ([Tables 2](#t2){ref-type="table"}, [3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}) and the increased risk of prostate cancer of long GGN repeats were more predominant in advanced prostate cancer cases ([Fig. 11](#f11){ref-type="fig"}). Meta-regression analysis did not detect any significant difference between subgroups ([Tables 2](#t2){ref-type="table"}, [3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}). Subgroup analysis showed that the result of CAG repeat length and risk of prostate cancer was robust ([Fig. 12](#f12){ref-type="fig"}).

Publication bias
----------------

Publication bias was detected using contour-enhanced funnel plot and Egger's linear regression method. Contour-enhanced funnel plots showed that publication bias might exist for the short versus long CAG repeat polymorphism ([Fig. 13](#f13){ref-type="fig"}) and no publication bias existed in the short versus long GGN repeat polymorphism ([Fig. 14](#f14){ref-type="fig"}). Egger's linear regression method supported the aforementioned conclusion (P = 0.004 for CAG repeats; P = 0.07 for GGN repeats).

Discussion
==========

The present meta-analysis summarizes the evidence to date regarding the association between CAG and GGN repeat polymorphisms of androgen receptor and the risk of prostate cancer. The results suggested that short CAG and GGN repeats in the androgen receptor gene were associated with increased risk of prostate cancer, especially in Caucasians.

The short CAG repeats (\<22) and short GGN repeats (≤16) carry a roughly 1.31- and 1.38-fold higher risk of developing prostate cancer compared with subjects with long CAG (≥22) repeats and long GGN repeats (\>16), respectively. Each decrement in CAG repeat presented 1.04-fold higher risk of developing prostate cancer. Prostate cancer cases presented an average 0.85 fewer CAG repeats than controls. In Caucasians, the aforementioned elevated risk was increased. This could be due to that more studies conducted in Caucasians, which provided greater statistical power for detecting small gene effect. Specifically, the prostate cancer cases in Caucasian population carried an average 1.09 fewer CAG repeats than controls. This difference might yield certain measurable biological impact in prostate carcinogenesis, such as early diagnosis and gene therapy.

An interaction between CAG and GGN repeat polymorphisms in increasing the prostate cancer susceptibility was documented by our meta-analysis. Haplotype analysis showed that short CAG and short GGN repeats carriers presented 2.06-fold higher risk of developing prostate cancer compared with long CAG and long GGN repeats carriers. Moreover, the short CAG repeats and long GGN repeats carriers presented 1.79-fold higher risk of developing prostate cancer compared with long CAG and long GGN repeats carriers.

In 2004, Zeegers *et al*.[@b6] published the first meta-analysis regarding the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk, in which included 23 articles with 19 retrospective case-control studies and 5 prospective case-control studies, comprising a total of 4274 cases and 5275 controls. They found that the presence of shorter repeats seemed to be modestly associated with prostate cancer risk. However, they did not found any significant difference in number of repeats between cases and controls. In 2012, Gu *et al*.[@b10] aggregated 27 articles to evaluate the relationship between CAG repeat polymorphism and prostate cancer risk. Their meta-analysis demonstrated that the CAG repeat polymorphism in androgen receptor gene with more than 20 repeats might confer a protective effect among the prostate cancer cases among men 45 years or older only. In 2013, Sun *et al*.[@b11] carried out another meta-analysis regarding the association between CAG repeat polymorphism and prostate cancer risk, which included 47 studies with 13 346 cases and 15 172 controls. They suggested that a short CAG repeat polymorphism might increase the risk of prostate cancer compared with the longer CAG repeat, especially in Caucasians and Asians. Compared with the previous meta-analysis[@b6][@b10][@b11], our meta-analysis was more comprehensively searched and our meta-analysis included 51 case-control studies (14 803 cases and 18 888 controls) for CAG repeats and 16 case-control studies (2986 cases and 3705 controls) for GGN repeats. In addition, our meta-analysis performed haplotype analysis and suggested that there exists an interaction between CAG and GGN repeat polymorphisms in increasing the prostate cancer susceptibility. Moreover, we found a significant difference in number of CAG repeat length between cases and controls, and the absolute difference in more than 1 repeat in Caucasians.

The present retrospective analysis has some limitations. First, the evidence of between study heterogeneity was apparent, and the heterogeneity might distort the conclusion of the current meta-analysis[@b67][@b68][@b69]. Additionally, the meta-regression analysis failed to identify the source of heterogeneity. Second, the standard of cutpoint of repeat length polymorphisms varied in different studies. This might in part contribute to the between study heterogeneity. Third, the screening policy of prostate cancer also varies between countries. Especially in United States, the prostate-specific antigen screening of the general population is more commonly used than other countries[@b6]. These different screening policies might also be responsible for the between study heterogeneity. Fourth, the publication bias was detected in the present meta-analysis for the association between CAG repeat polymorphism and risk of prostate cancer. The existing publication bias indicated that certain studies with negative results for the association between CAG repeat polymorphism and prostate cancer risk are under-represented in the literature. The publication bias also might distort the conclusion of the present meta-analysis. Ultimately, the meta-analysis is a secondary analysis; therefore, we could not handle the problem of between study heterogeneity.

In summary, our meta-analysis indicated that short CAG and GGN repeats in androgen receptor gene were associated with increased risk of prostate cancer, especially in Caucasians.

Additional Information
======================

**How to cite this article**: Weng, H. *et al*. Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. *Sci. Rep.* **7**, 40554; doi: 10.1038/srep40554 (2017).

**Publisher\'s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work has no funding.

**Author Contributions** H.W. and X.T.Z. designed this study; H.W. and S.L. searched databases and collected full-text papers; H.W., J.Y.H., Z.Q.H., X.Y.M., Y.C. and C.F. extracted and analyzed data; H.W. and X.T.Z. wrote the manuscript, all the authors reviewed the manuscript.

![Flow chart for this meta-analysis.](srep40554-f1){#f1}

![Sample size of the CAG repeat polymorphism.](srep40554-f2){#f2}

![Sample size of the GGN repeat polymorphism.](srep40554-f3){#f3}

![Forest plot of short CAG repeats versus long CAG repeats.](srep40554-f4){#f4}

![Forest plot of per one CAG repeat decrement and risk of prostate cancer risk.](srep40554-f5){#f5}

![Forest plot of difference in number of CAG repeat length between cases and controls.](srep40554-f6){#f6}

![Forest plot of short GGN repeats versus long GGN repeats.](srep40554-f7){#f7}

![Forest plot of per one GGN repeat decrement and risk of prostate cancer risk.](srep40554-f8){#f8}

![Forest plot of difference in number of GGN repeat length between cases and controls.](srep40554-f9){#f9}

![Haplotype analysis of CAG and GGN repeat polymorphisms and risk of prostate cancer.](srep40554-f10){#f10}

![Subgroup analysis of histology grade of prostate cancer.](srep40554-f11){#f11}

![Sensitivity analysis of CAG repeat decrement and risk of prostate cancer risk.](srep40554-f12){#f12}

![Contour-enhanced funnel plot of CAG repeat polymorphism.](srep40554-f13){#f13}

![Contour-enhanced funnel plot of GGN repeat polymorphism.](srep40554-f14){#f14}

###### Characteristics of included studies in the meta-analysis.

  Reference                         Country        Race      Study design    Control status   Age, yr (ca/co)   Advanced cases (%)   Sample size   Repeat cutpoint  
  ------------------------------ -------------- ----------- --------------- ---------------- ----------------- -------------------- ------------- ----------------- ----
  **CAG repeats**                                                                                                                                                   
  Irvine *et al*. 1995 (a)             US        Caucasian   Retrospective      Healthy           57.8/NR               46               57              39          22
  Irvine *et al*. 1995 (b)             US         African    Retrospective      Healthy           57.8/NR               46               57              44          22
  Irvine *et al*. 1995 (c)             US          Asian     Retrospective      Healthy           57.8/NR               46               57              39          22
  Giovannucci *et al*. 1997            US        Caucasian    Prospective       Healthy             NR                 30.7              587             588         22
  Hakimi *et al*. 1997                 US        Caucasian   Retrospective      Healthy           62.1/NR              42.4              59              370         17
  Ingles *et al*. 1997                 US        Caucasian   Retrospective      Healthy           57.8/NR               46               57              169         22
  Stanford *et al*. 1997               US        Caucasian   Retrospective      Healthy           54.9/54              45.9              281             266         22
  Platz *et al*. 1998                  US        Caucasian    Prospective       Healthy            62/NR               46.6              582             794         23
  Bratt *et al*. 1999                Sweden      Caucasian   Retrospective      Healthy           70.2/NR              1.6               160             186         22
  Correa-Cerro *et al*. 1999        Germany      Caucasian   Retrospective      Healthy          68.2/71.2              NR               132             105         22
  Edwards *et al*. 1999                UK        Caucasian   Retrospective      Healthy           68.1/NR              75.3              162             390         22
  Lange *et al*. 2000                  US        Caucasian   Retrospective      Healthy            64/NR                NR               133             305         22
  Xue *et al*. 2000                    US        Caucasian   Retrospective      Healthy          57.8/58.2              46               57              156         20
  Beilin *et al*. 2001             Australia     Caucasian   Retrospective      Healthy           67/66.6              39.2              448             456         22
  Latil *et al*. 2001                France      Caucasian    Prospective       Healthy          70.5/71.7             69.8              226             156         23
  Modugno *et al*. 2001                US        Caucasian   Retrospective      Healthy          68.9/73.6              NR               88              241         23
  Panz *et al*. 2001 (a)             Israel      Caucasian   Retrospective      Healthy            76/NR                30               20              20          22
  Panz *et al*. 2001 (b)          South Africa    African    Retrospective      Healthy            68/NR                30               20              20          22
  Balic *et al*. 2002                  US        Hispanic    Retrospective      Healthy            64/57                NR               82              145         18
  Chang *et al*. 2002                  US        Caucasian   Retrospective      Healthy           60.9/58               NR               210             180         22
  Chen *et al*. 2002                   US        Caucasian    Prospective       Healthy          61.2/60.8             11.5              300             300         22
  Gsur *et al*. 2002               Australia     Caucasian   Retrospective        BPH            65.9/66.5              NR               190             190         22
  Hsing *et al*. 2002                China         Asian     Retrospective      Healthy          72.2/71.9             62.6              190             300         22
  Mononen *et al*. 2002 (a)         Finland      Caucasian   Retrospective      Healthy           68.1/NR              48.1              461             574         18
  Mononen *et al*. 2002 (b)         Finland      Caucasian   Retrospective        BPH             68.1/NR              48.1              461             223         18
  Huang *et al*. 2003                China         Asian     Retrospective      Healthy          71.5/71.7             40.9              66              104         22
  Li *et al*. 2003 (a)               Sweden      Caucasian   Retrospective        BPH              69/67                NR               59              38          22
  Li *et al*. 2003 (b)               Japan         Asian     Retrospective        BPH              71/NR                NR               34              33          22
  dos Santos *et al*. 2003 (a)       Brazil      Caucasian   Retrospective      Healthy            65/58                NR               97              100         21
  dos Santos *et al*. 2003 (b)       Brazil       African    Retrospective      Healthy            65/58                NR               32              100         NR
  Gilligan *et al*. 2004               US         African    Retrospective      Healthy          66.7/55.5             24.5              118             576         22
  Visvanathan *et al*. 2004            US        Caucasian    Prospective       Healthy           66.1/66              45.8              164             324         22
  Gulnmira *et al*. 2004             China         Asian     Retrospective      Healthy          67.5/66.3              NR               31              80          22
  Li *et al*. 2004                   China         Asian     Retrospective      Healthy          67.9/67.1              60               105             190         22
  Freedman *et al*. 2005               US          Mixed      Prospective       Healthy            45-75                NR              2160            2036         22
  Mishra *et al*. 2005               India       Caucasian   Retrospective      Healthy          65.6/63.7              NR               113             133         22
  Platz *et al*. 2005                  US        Caucasian    Prospective       Healthy             NR                  NR               448             448         22
  Salinas *et al*. 2005                US        Caucasian   Retrospective      Healthy             NR                 33.8              553             523         22
  Andersson *et al*. 2006            Sweden      Caucasian   Retrospective      Healthy           76.2/NR               NR               137             125         23
  Vijayalakshmi *et al*. 2006        India       Caucasian   Retrospective      Mixed\#           67.5/66               NR               87              120         22
  Lindstrom *et al*. 2006            Sweden      Caucasian   Retrospective      Healthy             NR                  48              1461             796         22
  Okugi *et al*. 2006                Japan         Asian     Retrospective      Healthy           69.9/71               NR               102             117         22
  Sieh *et al*. 2006 (a)               US        Caucasian    Prospective       Healthy           77.1/NR              31.9              160             320         22
  Sieh *et al*. 2006 (b)               US         African     Prospective       Healthy           74.9/NR              45.5              33              71          22
  Du *et al*. 2006                   China         Asian     Retrospective      Healthy             NR                  NR               35              15          NR
  Mittal *et al*. 2007               India       Caucasian   Retrospective      Healthy          66.2/64.1              NR               135             142         22
  Das *et al*. 2007 (a)            Singapore       Asian     Retrospective      Healthy            66/69                NR               47              46          22
  Das *et al*. 2007 (b)            Singapore       Asian     Retrospective        BPH              66/67                NR               47              130         22
  Lange *et al*. 2007                  US         African    Retrospective      Healthy           40--79                NR               180             840         22
  Neto *et al*. 2008                 Brazil      Caucasian   Retrospective      Healthy            64/59                NR               49              51          21
  Nicolaiew *et al*. 2009            France      Caucasian   Retrospective      Healthy            67/63                NR              1045             814         17
  Kuasne *et al*. 2010               Brazil      Caucasian   Retrospective      Healthy          65.3/63.8             38.8              160             160         20
  Price *et al*. 2010 (a)              US        Caucasian    Prospective       Healthy          63.4/63.6              NR              1082            1080         19
  Price *et al*. 2010 (b)              US         African     Prospective       Healthy          63.4/63.6              NR               47              128         19
  Ashtiani *et al*. 2011 (a)          Iran       Caucasian   Retrospective      Healthy             NR                  NR               110             100         21
  Ashtiani *et al*. 2011 (b)          Iran       Caucasian   Retrospective        BPH               NR                  NR               110             99          21
  Figg *et al*. 2014                   US        Caucasian    Prospective       Healthy           60.4/NR               NR               195            1344         19
  Yoo *et al*. 2014                    US        Caucasian    Prospective       Healthy           66/63.2              7.9               291            1221         22
  Zhai *et al*. 2014                 China         Asian     Retrospective      Healthy          67.4/67.9             38.2              68              60          22
  Han *et al*. 2015                  China         Asian     Retrospective      Healthy             NR                  NR               70              70          18
  Liang *et al*. 2015                China         Asian     Retrospective      Healthy            64/58                NR               95              98          22
  **GGN repeats**                                                                                                                                                   
  Irvine *et al*. 1995 (a)             US        Caucasian   Retrospective      Healthy           57.8/NR               46               57              37          16
  Irvine *et al*. 1995 (b)             US         African    Retrospective      Healthy           57.8/NR               46               57              41          16
  Irvine *et al*. 1995 (c)             US          Asian     Retrospective      Healthy           57.8/NR               46               57              37          16
  Hakimi *et al*. 1997                 US        Caucasian   Retrospective      Healthy           62.1/NR              42.4              54              110         14
  Stanford *et al*. 1997               US        Caucasian   Retrospective      Healthy           54.9/54              45.9              257             250         16
  Platz *et al*. 1998                  US        Caucasian    Prospective       Healthy            62/NR               46.6              582             794         16
  Correa-Cerro *et al*. 1999        Germany      Caucasian   Retrospective      Healthy          68.2/71.2              NR               132             105         16
  Edwards *et al*. 1999                UK        Caucasian   Retrospective      Healthy           68.1/NR              75.3              162             390         16
  Chang *et al*. 2002                  US        Caucasian   Retrospective      Healthy           60.9/58               NR               198             174         16
  Chen *et al*. 2002                   US        Caucasian    Prospective       Healthy          61.2/60.8             11.5              300             300         16
  Hsing *et al*. 2002                China         Asian     Retrospective      Healthy          72.2/71.9             62.6              178             295         16
  Salinas *et al*. 2005                US        Caucasian   Retrospective      Healthy           40--64               33.8              553             520         16
  Vijayalakshmi *et al*. 2006        India       Caucasian   Retrospective       Mixed            67.5/66               NR               86              119         21
  Mittal *et al*. 2007               India       Caucasian   Retrospective      Healthy          66.2/64.1              NR               135             142         22
  Lange *et al*. 2007                  US         African    Retrospective      Healthy           40--79                NR               129             340         16
  Neto *et al*. 2008                 Brazil      Caucasian   Retrospective      Healthy            64/59                NR               49              51          17

NR, not report.

###### The results of overall and subgroup analyses of the association between CAG repeats and prostate cancer risk.

                              No. studies       OR (95% CI)       P~OR~    I^2^   P~heterogeneity~   P~interaction~
  -------------------------- ------------- --------------------- -------- ------ ------------------ ----------------
  **Short versus long**           59        1.31 (1.16 to 1.47)   \<0.01   74.9        \<0.01               
  Ethnicity                                                                                               0.07
   Caucasian                      39        1.39 (1.20 to 1.61)   \<0.01   80.1        \<0.01               
   Asian                          12        1.24 (0.93 to 1.65)    0.15     50          0.02                
   African                         6        0.86 (0.66 to 1.12)    0.26    13.5         0.33                
   Hispanic                        1        2.69 (1.20 to 6.01)    0.02     NA           NA                 
  Study design                                                                                            0.05
   Retrospective                  46        1.43 (1.21 to 1.70)   \<0.01   78.9        \<0.01               
   Prospective                    13        1.09 (1.00 to 1.20)    0.06    17.2         0.27                
  Control status                                                                                          0.58
   Healthy                        52        1.23 (1.11 to 1.37)   \<0.01    69         \<0.01               
   BPH                             6        1.68 (0.73 to 3.87)    0.23    86.4        \<0.01               
  **Increment per repeat**        33        1.04 (1.02 to 1.07)   \<0.01   83.4        \<0.01               
  Ethnicity                                                                                               0.41
   Caucasian                      19        1.06 (1.02 to 1.10)   \<0.01   89.9        \<0.01               
   Asian                          10        1.03 (1.00 to 1.06)    0.06    19.5         0.26                
   African                         3        1.01 (0.98 to 1.04)    0.39     0           0.84                
   Latino                          1        1.01 (0.98 to 1.05)    0.44     NA           NA                 
  Study design                                                                                            0.16
   Retrospective                  23        1.08 (1.04 to 1.12)   \<0.01   84.6        \<0.01               
   Prospective                    10        1.01 (0.99 to 1.01)    0.98    9.6          0.35                
  Control status                                                                                          0.14
   Healthy                        29        1.03 (1.01 to 1.06)   \<0.01   76.8        \<0.01               
   BPH                             4        1.24 (1.00 to 1.53)    0.05    95.1        \<0.01               

BPH, benign prostatic hyperplasia; OR, odds ratio; CI, confidence interval; NA, not available.

###### Results of length of CAG repeats and risk of prostate cancer.

                              No. studies        MD (95% CI)         P~MD~    I^2^   P~heterogeneity~   P~interaction~
  -------------------------- ------------- ------------------------ -------- ------ ------------------ ----------------
  **Length of CAG repeat**        23        −0.85 (−1.28 to −0.42)   \<0.01   88.7        \<0.01               
  Ethnicity                                                                                                  0.11
   Caucasian                      14        −1.09 (−1.65 to −0.53)   \<0.01   92.9        \<0.01               
   Asian                           8        −0.32 (−0.86 to 0.22)     0.25    32.1         0.17                
   African                         1        −0.40 (−1.69 to 0.89)     0.55     NA           NA                 
  Study design                                                                                               0.07
   Retrospective                  20        −1.06 (−1.60 to −0.51)   \<0.01   88.2        \<0.01               
   Prospective                     3         0.14 (−0.06 to 0.34)     0.17    0.0          0.88                
  Control status                                                                                             0.81
   Healthy                        19        −0.72 (−1.15 to −0.29)   \<0.01   85.8        \<0.01               
   BPH                             4        −1.40 (−3.19 to 0.38)     0.12    94.5        \<0.01               

BPH, benign prostatic hyperplasia; MD, mead difference; CI, confidence interval; NA, not available.

###### Results of the association between GGN repeats and prostate cancer.

                           No. studies        OR (95% CI)        P~OR~   I^2^   P~heterogeneity~   P~interaction~
  ----------------------- ------------- ----------------------- ------- ------ ------------------ ----------------
  **Short versus long**        16         1.38 (1.05 to 1.82)    0.02    69.1        \<0.01               
  Ethnicity                                                                                             0.52
   Caucasian                   12         1.24 (1.01 to 1.52)    0.04     38          0.09                
   Asian                        2        8.96 (0.25 to 318.05)   0.51    86.6         0.01                
   African                      2        2.02 (0.25 to 16.24)    0.23     94         \<0.01               
  Study design                                                                                          0.37
   Retrospective               14         1.46 (1.09 to 1.97)    0.01    71.8        \<0.01               
   Prospective                  2         0.70 (0.17 to 2.80)    0.61    49.9         0.16                
  Control status                                                                                        0.57
   Healthy                     15         1.44 (1.07 to 1.93)    0.02    70.5        \<0.01               
   Mixed                        1         0.91 (0.52 to 1.58)    0.73     NA           NA                 

OR, odds ratio; CI, confidence interval; NA, not available.

[^1]: These authors contributed equally to this work.
